Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis
Public ClinicalTrials.gov record NCT03425396. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blinded, Adaptive Phase 2 Study to Evaluate the Safety and Efficacy of Oral Omadacycline and Oral Nitrofurantoin in the Treatment of Female Adults With Cystitis
Study identification
- NCT ID
- NCT03425396
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Paratek Pharmaceuticals Inc
- Industry
- Enrollment
- 225 participants
Conditions and interventions
Conditions
Interventions
- Omadacycline tablets Drug
- Nitrofurantoin capsules Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 3, 2018
- Primary completion
- May 14, 2019
- Completion
- Jun 4, 2019
- Last update posted
- Jun 8, 2020
2018 – 2019
United States locations
- U.S. sites
- 23
- U.S. states
- 9
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 106 | Chula Vista | California | 91911 | — |
| Site 101 | La Mesa | California | 91942 | — |
| Site 109 | Los Angeles | California | 90017 | — |
| Site 114 | Aventura | Florida | 33180 | — |
| Site 102 | DeLand | Florida | 32720 | — |
| Site 103 | Hialeah | Florida | 33015 | — |
| Site 125 | Jacksonville | Florida | 32256 | — |
| Site 121 | Miami | Florida | 33126 | — |
| Site 130 | Miami | Florida | 33126 | — |
| Site 115 | Miami | Florida | 33134 | — |
| Site 127 | Miami Springs | Florida | 33166 | — |
| Site 126 | Orlando | Florida | 82306 | — |
| Site 113 | Newton | Kansas | 67114 | — |
| Site 110 | Wichita | Kansas | 67207 | — |
| Site 112 | Omaha | Nebraska | 68144 | — |
| Site 132 | Las Vegas | Nevada | 89106 | — |
| Site 108 | Las Vegas | Nevada | 89109 | — |
| Site 122 | Berlin | New Jersey | 08009 | — |
| Site 118 | Raleigh | North Carolina | 27612 | — |
| Site 104 | Jackson | Tennessee | 38305 | — |
| Site 105 | Smyrna | Tennessee | 37167 | — |
| Site 131 | Houston | Texas | 77061 | — |
| Site 120 | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03425396, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 8, 2020 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03425396 live on ClinicalTrials.gov.